Pfizer readies ‘robust’ manufacturing capabilities to deliver 2 COVID-19 variant vaccines 09-Aug-2022 By Nick Taylor Pfizer is planning to deliver COVID-19 vaccines against two sets of omicron subvariants in the autumn in the belief its “robust manufacturing capabilities” are up to the task.
Pfizer predicts $54bn in 2022 revenue from Comirnaty and Paxlovid 08-Feb-2022 By Rachel Arthur Pfizer forecasts $32bn in revenue for COVID-19 vaccine Comirnaty, and $22bn for oral COVID-19 treatment Paxlovid, in 2022.